Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354614 · ClinicalTrials.gov registry record
Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)
A clinical trial, sponsored by ResMed.
- Completed
- Registry status
- 81
- Enrollment target
NCT00354614: Completed study, sponsored by ResMed.
NCT00354614 is a clinical trial that has completed, run by ResMed. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00354614 has completed, sponsored by ResMed.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The primary endpoints for this study are that the AL validation will 1) achieve a sensitivity of greater than 80% for AHI values greater than or equal to 15, and 2) demonstrate a correlation coefficient of r=0.75 indicating strong correlation between the AHI of diagnostic PSG and AL.
Primary Outcome
Comparison of sensitivity and specificity of ApneaLink to polysomnography with an apnea hypopnea index (AHI) cut-off of 15 or greater
Interventions
- DEVICE ApneaLink Sleep Screener
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-07 |
What the finished NCT00354614 record still lists
NCT00354614 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ApneaLink Sleep Screener is the first listed.
NCT00354614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00354614 about?
NCT00354614 is a clinical study titled "Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)". The primary endpoints for this study are that the AL validation will 1) achieve a sensitivity of greater than 80% for AHI values greater than or equal to 15, and 2) demonstrate a correlation coefficient of r=0.75 indicating strong correlation between the AHI of diagnostic PSG and AL.
What is the current status of trial NCT00354614?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2006-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00354614?
The interventions under investigation include: ApneaLink Sleep Screener (DEVICE).
Who is sponsoring clinical trial NCT00354614?
This trial is sponsored by ResMed, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia